2 New HCV Drug Treatment Abstracts with Links

[Guest guest]

Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of

Hepatitis C Virus DNA Vaccine

From the PharmaLive.com News Archive - Mar. 14, 2011

Inovio Pharmaceuticals announced today that its partner, ChronTech Pharma AB

(formerly Tripep AB), has initiated a Phase IIb clinical study of its ChronVac-C

DNA vaccine for hepatitis C virus (HCV), delivered by Inovio's proprietary

electroporation DNA vaccine delivery technology, in combination with standard of

care.

Biotron -- Stage One of Landmark Hepatitis C Drug Trial Completed

From the PharmaLive.com News Archive - Mar. 10, 2011

Australian drug development company Biotron Limited has completed stage one of a

landmark human trial of its lead Hepatitis C drug candidate, BIT225. Twelve

patients have been dosed in the first half of the trial being undertaken by

ACLIRES. All are infected with the most common strain of the Hepatitis C virus,

genotype 1.

[Guest guest]

Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of

Hepatitis C Virus DNA Vaccine

From the PharmaLive.com News Archive - Mar. 14, 2011

Inovio Pharmaceuticals announced today that its partner, ChronTech Pharma AB

(formerly Tripep AB), has initiated a Phase IIb clinical study of its ChronVac-C

DNA vaccine for hepatitis C virus (HCV), delivered by Inovio's proprietary

electroporation DNA vaccine delivery technology, in combination with standard of

care.

Biotron -- Stage One of Landmark Hepatitis C Drug Trial Completed

From the PharmaLive.com News Archive - Mar. 10, 2011

Australian drug development company Biotron Limited has completed stage one of a

landmark human trial of its lead Hepatitis C drug candidate, BIT225. Twelve

patients have been dosed in the first half of the trial being undertaken by

ACLIRES. All are infected with the most common strain of the Hepatitis C virus,

genotype 1.

[Guest guest]

Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of

Hepatitis C Virus DNA Vaccine

From the PharmaLive.com News Archive - Mar. 14, 2011

Inovio Pharmaceuticals announced today that its partner, ChronTech Pharma AB

(formerly Tripep AB), has initiated a Phase IIb clinical study of its ChronVac-C

DNA vaccine for hepatitis C virus (HCV), delivered by Inovio's proprietary

electroporation DNA vaccine delivery technology, in combination with standard of

care.

Biotron -- Stage One of Landmark Hepatitis C Drug Trial Completed

From the PharmaLive.com News Archive - Mar. 10, 2011

Australian drug development company Biotron Limited has completed stage one of a

landmark human trial of its lead Hepatitis C drug candidate, BIT225. Twelve

patients have been dosed in the first half of the trial being undertaken by

ACLIRES. All are infected with the most common strain of the Hepatitis C virus,

genotype 1.

[Guest guest]

Inovio Pharmaceuticals' Partner ChronTech Initiates Phase II Clinical Trial of

Hepatitis C Virus DNA Vaccine

From the PharmaLive.com News Archive - Mar. 14, 2011

Inovio Pharmaceuticals announced today that its partner, ChronTech Pharma AB

(formerly Tripep AB), has initiated a Phase IIb clinical study of its ChronVac-C

DNA vaccine for hepatitis C virus (HCV), delivered by Inovio's proprietary

electroporation DNA vaccine delivery technology, in combination with standard of

care.

Biotron -- Stage One of Landmark Hepatitis C Drug Trial Completed

From the PharmaLive.com News Archive - Mar. 10, 2011

Australian drug development company Biotron Limited has completed stage one of a

landmark human trial of its lead Hepatitis C drug candidate, BIT225. Twelve

patients have been dosed in the first half of the trial being undertaken by

ACLIRES. All are infected with the most common strain of the Hepatitis C virus,

genotype 1.